These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24156952)

  • 41. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].
    Miró JM; Manzardo C; Zamora L; Pumarola T; Herreras Z; Gallart T; Gatell JM
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):759-72. PubMed ID: 22078726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
    Sungkanuparph S; Anekthananon T; Hiransuthikul N; Bowonwatanuwong C; Supparatpinyo K; Mootsikapun P; Chetchotisakd P; Kiertiburanakul S; Tansuphaswadikul S; Buppanharun W; Manosuthi W; Techasathit W; Ratanasuwan W; Tantisiriwat W; Suwanagool S; Leechawengwongs M; Ruxrungtham K;
    J Med Assoc Thai; 2008 Dec; 91(12):1925-35. PubMed ID: 19133532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
    Mocroft A; Bannister WP; Kirk O; Kowalska JD; Reiss P; D'Arminio-Monforte A; Gatell J; Fisher M; Trocha H; Rakhmanova A; Lundgren JD;
    Antivir Ther; 2012; 17(7):1291-300. PubMed ID: 23013779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does pregnancy affect the early response to cART?
    Rachas A; Warszawski J; Le Chenadec J; Legeai C; Teglas JP; Goujard C; Rouzioux C; Mandelbrot L; Tubiana R; Meyer L
    AIDS; 2013 Jan; 27(3):357-67. PubMed ID: 23079802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.
    Wang H; Li Y; Zhang C; Han Y; Zhang X; Zhu T; Li T
    AIDS; 2012 Sep; 26(14):1755-63. PubMed ID: 22614885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
    Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
    HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients.
    AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology
    Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(7):467-475. PubMed ID: 29793873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. German-Austrian recommendations for HIV-therapy in pregnancy--common declaration of The German AIDS-society (DAIG), The Austrian AIDS-society (OEAG) as well as The Robert-Koch Institute Berlin (RKI), The German Association of Physicians specialized in HIV Care (DAGNAE), The German Society of Pediatric and Youth Medicine (DGKJ), The German AIDS Pediatric Association (PAAD), The German Society of Obstetrics and Gynecology (DGGG), The National Reference Center for Retroviruses (NRZ), German AIDS Assistance (DAH).
    Buchholz B; Marcus U; Beichert M; Grubert T; Gingelmaier A; Kaestner R; Grosch-Woerner I; Brockmeyer NH; ; ; ; ; ; ; ; ;
    Eur J Med Res; 2002 Oct; 7(10):417-33. PubMed ID: 12435621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends and the associated factors of optimal immunological response and virological response in late anti-retroviral therapy initiation HIV cases in Taiwan from 2009 to 2020.
    Lee CY; Lin YP; Lin CY; Chen TC; Kuo SH; Lo SH; Wang SF; Lu PL
    J Infect Public Health; 2024 Feb; 17(2):339-348. PubMed ID: 38194765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.
    Miro JM; Manzardo C; Mussini C; Johnson M; d'Arminio Monforte A; Antinori A; Gill MJ; Sighinolfi L; Uberti-Foppa C; Borghi V; Sabin C;
    PLoS One; 2011; 6(10):e26009. PubMed ID: 22043301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Budget impact analysis of antiretroviral therapy. A reflection based on the GESIDA guidelines].
    Grupo de trabajo de la Cohorte VACH
    Gac Sanit; 2012; 26(6):541-6. PubMed ID: 22498716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus.
    Miralles P; Navarro JT; Berenguer J; Gómez Codina J; Kwon M; Serrano D; Díez-Martín JL; Villà S; Rubio R; Menárguez J; Ribera Santasusana JM
    Med Clin (Barc); 2018 Jul; 151(1):39.e1-39.e17. PubMed ID: 29357988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders].
    ; Podzamczer Palter D; Muñoz-Moreno JA; Alcolea Rodríguez D; Alonso Villaverde C; Antela López A; Blanch Andreu J; Casado Osorio JL; Galindo Puerto MJ; Garolera i Freixa M; Locutura Rupérez J; Lleó Bisa A; Prats París A; Pérez-Valero I; Portilla Sogorb J; Rovira Cañellas A; Téllez Molina MJ; Tiraboschi JM; Vergara Moragues E; Arribas López JR; Goenaga Sánchez MÁ; de León-Naranjo FL; Martínez Chamorro E; Polo Rodríguez R; Muñoz-Moreno JA; Podzamczer D
    Enferm Infecc Microbiol Clin; 2014 Jan; 32(1):37-47. PubMed ID: 23642283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.